hotspot -WSS

hotspot

author：fashion 2025-10-01 20:14:57 - browse：44381

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

WSS

How a small hospital in rural Puerto Rico survived Hurricane Maria

Drastic changes should bring profitability, startup health insurers say

Wegovy’s successful heart trial raises vital question about weight loss

American woman, child freed after being kidnapped in Haiti last month

Wegovy’s successful heart trial raises vital question about weight loss

NIH trials fail to test meaningful long Covid therapies, experts say

explore

hotspot

focus

Tori Bowie and the unacceptable rates of Black maternal death

Wegovy trial has doctors encouraged over new possibilities

Walensky prepares to leave CDC — and Congress — behind

Deliver public health messages at the right time

Activists slam private health insurers over coverage restrictions

BIO to announce reorganization, senior leaders expected to depart

Heart attack and stroke risk calculators need revising

Anavex keeps shifting the goalposts in its clinical trials

Cancer drug shortages should be causing more outrage

Warren pushes Witty on UnitedHealth's control over physicians

focus

BIO to announce reorganization, senior leaders expected to depart

Naloxone nonprofit donates 200,000 doses after FDA approval

What to know about Virgin Galactic's 1st mission taking paying customers to space

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Is it ever OK for doctors to lie to their patients?

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

leisure time

Wikipedia

knowledge

knowledge